Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus, Almac Partner to Offer Screening, Profiling Services

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BioFocus and Almac today announced a deal to provide compound screening and profiling services based on Almac's Flexyte fluorescence lifetime assays to BioFocus' customers.

BioFocus has launched an FLT screening and profiling service using the Flexyte assay platform and is offering services against targets such as proteases, phosphatases, and kinases.

"The unique properties of FLT have also been harnessed to open up access to previously inaccessible epigenetics target classes," the firms said in a joint statement.

Approaches that can be used on the Flexyte platform include fragment-based screens and kinetic profiling, they added.

Financial and other terms of the deal were not disclosed.

Almac is a Craigavon, Northern Ireland-based drug development services firm. UK-based BioFocus is the drug discovery services division of Galapagos.